Safety and Pharmacokinetics of Lopinavir in HIV/HCV Coinfected Patients with Advanced Liver Disease

REFERENCES

• Carr A, Cooper DA. Adverse effects of antiretroviral ther-apy. Lancet. 2000;356:1423–1430.
   PubMed Web of Science ®Google Scholar
• Wit F, Weyerling GJ, Weel J, et al. Incidence of and risk fac-tors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002186: 23–31.
   Google Scholar
• Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Rev. 2003;5:36–43
   PubMedGoogle Scholar
• Saves M, Vandentoren S, Daucourt V, et al. Severe hepati-tis cytolysis: incidence and risk factors in patients treated with antiretroviral combinations (Aquitaine Cohort, France 1996-1998). AIDS. 1999;13:F115–F118.
   Web of Science ®Google Scholar
• D'Arminio, Monforte A, Bugarini R, Pezzotti P, et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 200128: 114–123.
   Google Scholar
• Sulkowski MS, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immu-nodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74–80.
   PubMed Web of Science ®Google Scholar
• Aranzabal L, Casado JL, Moya J, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis. 2005;40:588–593.
   PubMed Web of Science ®Google Scholar
• Palacios R, Vergara S, Rivero A, et al. Low incidence of severe liver events in HIV patients with and without hepati-tis C or B coinfection receiving lopinavir/ritonavir. HIV Clin Trials. 2006;7:319–323.
   PubMed Web of Science ®Google Scholar
• Bonfanti P, Ricci E, Penco G, et al. Low incidence of hepa-totoxicity in a cohort of HIV patients treated with lopinavir/ ritonavir. AIDS. 2005;19:1433–1434.
   PubMed Web of Science ®Google Scholar
• van Waterschoot RA, ter Heine R, Wagenaar E et al. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Phar-macoL 2010;160:1224–1233.
   PubMed Web of Science ®Google Scholar
• Gonzalez de Requena D, Nunez M, Jimenez-Nacher I, et al. Liver toxicity of lopinavir/ritonavir-containing regi-mens in HIV-infected patients with or without hepatitis C virus (HCV) co-infection. AIDS Res Human Retroviruses. 2004;20: 698–700.
   PubMed Web of Science ®Google Scholar
• Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplow-itz N, et al. Formulation and application of a numerical scor-ing system for assessing histological activity in asymptom-atic chronic active hepatitis. Hepatology. 1981;1: 431–435.
   PubMed Web of Science ®Google Scholar
• Poynard T, Ratziu V, Benmanov Y, Di Martino V, Bedossa P, Opolon P. Fibrosis in patients with hepatitis C: detection and significance. Semin Liver Dis. 2000;20:47–55.
   PubMed Web of Science ®Google Scholar
• Dickinson L, Robinson L, Tjia J et al. Simultaneous deter-mination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatogra-phy-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;829:82–90.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS. Management of hepatic complications in HIV infected persons. J Infect Dis. 2008,197:S279–293.
   PubMed Web of Science ®Google Scholar
• Meraviglia P, Schiavini M, Castagna A, et al. Lopinavir/ ritonavir in HIV antiretroviral-experienced patients: evalu-ation of risk factors for liver enzyme elevation. HIV Med 2004;5:334–343.
   PubMed Web of Science ®Google Scholar
• Pineda JA, Palacios R, Rivero A, et al. Low incidence of severe liver toxicity in patients receiving antiretroviral com-binations including atazanavir. J Antimicrob Chemother. 2006;23:1016–1017.
   Web of Science ®Google Scholar
• Curran A, Gutierrez M, Deig E, et al. Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment experienced patients. J Antimicrob Chemother 2010;65: 2195–2203.
   PubMed Web of Science ®Google Scholar
• Rockstroh J, Teppler H, Zhao J, et al. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection. HIV Med. 2011. doi: 10.1111/j.1468-1293.2011.00933.x
   Web of Science ®Google Scholar
• Ayoub A, Alston S, Goodrich J, et al. Hepatic safety and tolerability in the maraviroc clinical development program. AIDS. 2010;24:2743–2750.
   PubMed Web of Science ®Google Scholar
• Moltó J, Valle M, Blanco A, et al. Lopinavir/ritonavir phar-macokinetics in HIV and hepatitis C virus coinfected patients without liver function impairment: influence of liver fibrosis. Clin Pharmacokinet. 2007;46:85–92.
   PubMed Web of Science ®Google Scholar
• Peng JZ, Pulido F, Causemaker SJ, et al. Pharmacoki-netics of lopinavir/ritonavir in HIV/hepatitis C virus coin-fected subjects with hepatic impairment. J Clin PharmacoL 2006;46:265–274.
   PubMed Web of Science ®Google Scholar
• Barreiro P, Rodriguez-Novoa S, Labarga P, et al. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with crhronic hepatitis C. J Infect Dis. 2007;195:973–979.
   PubMed Web of Science ®Google Scholar
• Micheli V, Regazzi M, Dickinson L, et al. Lopinavir/ritonavir pharmacokinetics in HIV/HCV coinfected patients with or without cirrhosis. Ther Drug MoniL 2008;30:306–313.
   PubMed Web of Science ®Google Scholar
• Gatti F, Nasta P, Loregian A, et al. Unboosted fosampre-navir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV related cirrhosis. J Antimicrob Chemother. 2009;63:575–578.
   PubMed Web of Science ®Google Scholar
• Dominguez S, Ghosn J, Peytavin G, et al. Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV coinfected patients: the NEPA-DOSE study. J Antimicrob Chemother. 2010;65:2445–2449.
   PubMed Web of Science ®Google Scholar
• Wyles DL, Gerber JG. Antiretroviral drug pharmacokinet-ics in hepatitis with hepatic dysfunction. Clin Infect Dis. 2005;40:174–181.
   PubMed Web of Science ®Google Scholar
• George J, Murray M, Byth K, Farrell G. Differential altera-tions of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology. 1995; 21:120–128.
   PubMed Web of Science ®Google Scholar
• Guengerich F, Turvey C. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Phar-macol Exp Ther 1991;256:1189–1194.
   PubMed Web of Science ®Google Scholar
• Nettles RE, Kiefer TL, Parsons T, et al. Marked intraindi-vidual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis. 2006;42:1189–1196.
   PubMed Web of Science ®Google Scholar
• Canta F, Marrone R, Bonora S, et al. Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus coinfected patients. J Antimicrob Chemother 2005;13:281–285.
   Google Scholar